CTLA-4 Ig (Abatacept) FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN RELATIVES AT-RISK FOR TYPE 1 DIABETES MELLITUS
Diseases and Conditions Researched
Abnormal Glucose Tolerance; Type 1 Diabetes
What is the purpose of this trial?
The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial.
All subjects will receive close monitoring for development of AGT or T1DM. Subjects will receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess the safety, efficacy, and mode of action of Abatacept to prevent AGT and T1DM.
The primary objective is to determine whether intervention with Abatacept will prevent or delay the development of AGT in at-risk autoantibody positive non-diabetic relatives of patients with T1DM.
Secondary outcomes include: the effect of Abatacept on the incidence of T1DM analyses of C-peptide and other measures from the OGTT safety and tolerability and mechanistic outcomes.
Click here for detailed participation information for this trial.
|Sponsor:||National Institute of Diabetes and Digestive & Kidney Diseases|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.